Cited by 17Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsArtificial Intelligence in Healthcare

Identifying progression-specific Alzheimer’s subtypes using multimodal transformer

Open access
Machado Reyes, Diego, Chao, Hanqing, Hahn, Juergen, Shen, Li, Yan, Pingkun, for the Alzheimer’s Disease Neuroimaging Initiative·2024·Journal of Personalized Medicine

Abstract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease, yet its current treatments are limited to stopping disease progression. Moreover, the effectiveness of these treatments remains uncertain due to the heterogeneity of the disease. Therefore, it is essential to identify disease subtypes at a very early stage. Current data-driven approaches can be used to classify subtypes during later stages of AD or related disorders, but making predictions in the asymptomatic or prodromal stage is challenging. Furthermore, the classifications of most existing models lack explainability, and these models rely solely on a single modality for assessment, limiting the scope of their analysis. Thus, we propose a multimodal framework that utilizes early-stage indicators, including imaging, genetics, and clinical assessments, to classify AD patients into progression-specific subtypes at an early stage. In our framework, we introduce a tri-modal co-attention mechanism (Tri-COAT) to explicitly capture cross-modal feature associations. Data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (slow progressing = 177, intermediate = 302, and fast = 15) were used to train and evaluate Tri-COAT using a 10-fold stratified cross-testing approach. Our proposed model outperforms baseline models and sheds light on essential associations across multimodal features supported by known biological mechanisms. The multimodal design behind Tri-COAT allows it to achieve the highest classification area under the receiver operating characteristic curve while simultaneously providing interpretability to the model predictions through the co-attention mechanism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jpm14040421

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tri-COAT demonstrates that hippocampal atrophy modulates the predictive contribution of lipidomic and genomic features, bridging molecular changes with regional neurodegeneration.

    “Additionally, multimodal attention networks such as Tri-COAT demonstrate that hippocampal atrophy modulates the predictive contribution of lipidomic and genomic features, bridging molecular changes with regional neurodegeneration264.”

    From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [264]

    Section 4.3 reports that Tri-COAT learned putative associations among genetic features, brain regions, and clinical symptoms. It does not report lipidomic features or demonstrate that hippocampal atrophy modulates the predictive contribution of lipidomic and genomic features; Section 3.1 describes the model inputs as imaging, genotype, and clinical data. No page numbers are available in our copy. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [25]Su C. Hou Y. Xu J. Xu J. Brendel M. Maasch J.R.M.A. Bai Z. Zhang H. Zhu Y. Henchcliffe C. Parkinson’s Disease Progression, 2022. Pages: 2021.07.18.21260731 medRxiv 2022 2021.07.18.21260731 10.1101/2021.07.18.21260731 · DOI
  2. [34]Ba J.L. Kiros J.R. Hinton G.E. Layer Normalization arXiv 2016 1607.06450
  3. [35]Vaswani A. Shazeer N. Parmar N. Uszkoreit J. Jones L. Gomez A.N. Kaiser L. Polosukhin I. Attention is All you Need Proceedings of the Advances in Neural Information Processing Systems Curran Associates, Inc. Red Hook, NY, USA 2017 Volume 30

Cited by

Sorted by citations

Authors
Machado Reyes, D., Chao, H., Hahn, J., Shen, L., Yan, P., & Initiative, F. T. A. D. N.
Affiliations
  • Department of Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA
  • Rensselaer Polytechnic Institute (US)
  • University of Pennsylvania (US)
Corresponding author
Yan, Pingkun
Venue
Journal of Personalized Medicine
Publisher
MDPI AG
Published
2024-04-15
Volume
14
Issue
4
Pages
421
ISSN
2075-4426 (ISSN-L)
OpenAlex
W4394807540
Cited by
17
References
47
Citations by year
2026: 10 · 2025: 5 · 2024: 2
FWCI
5.00
Type
journal article
Language
en
Open access
Locations
  • Journal of Personalized Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • training grant (T32AG078123, 2046708, 1837964, U01 AG066833, U01 AG068057, RF1 AG063481)
  • NSF CAREER (T32AG078123, 2046708, 1837964, U01 AG066833, U01 AG068057, RF1 AG063481)
  • NSF IIS (T32AG078123, 2046708, 1837964, U01 AG066833, U01 AG068057, RF1 AG063481)
  • NIH (T32AG078123, 2046708, 1837964, U01 AG066833, U01 AG068057, RF1 AG063481)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Health Professions › Health Information Management › Artificial Intelligence in Healthcare
Keywords
Alzheimer's disease, disease subtypes, disease progression, multimodal classification, co-attention, prodromal Alzheimer's disease, neuroimaging, genetic data, clinical evaluation, explainable AI, ADNI

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review